Who is Hunterian? 

Hunterian is a cutting-edge gene editing company founded by Johns Hopkins geneticist and CRISPR expert Dr. Vinod Jaskula-Ranga. Dedicated to curing rare diseases, Hunterian is harnessing the full potential of CRISPR to develop groundbreaking genetic therapies. Their programs target Becker and Duchenne muscular dystrophy (BMD/DMD), cystic fibrosis, neurodegenerative diseases, eye diseases, and more.

Hunterian is at the forefront of genetic medicine, pushing the boundaries of what’s possible with CRISPR. Their groundbreaking work has earned them a Phase 1 National Institutes of Health (NIH) Targeted Genome Editor Delivery (TARGETED) Challenge Award for advancing delivery systems for CRISPR genome editing.

With 18 patents already secured and dozens more pending, Hunterian’s innovative approach—backed by cutting-edge research and NIH recognition—is laying the foundation for life-changing treatments. Their work offers real hope to those affected by rare diseases, moving us closer to a future where these conditions can be cured.

What Is Strongest Hearts Doing?

Strongest Hearts is committed to funding life-changing research—93% of every dollar raised goes directly to Hunterian to accelerate therapeutic development.

Where is this Happening?

This groundbreaking work is taking place in labs in Baltimore, Hunterian’s headquarters in Boston, and The Jackson Laboratory in Bar Harbor, Maine.

Why this Approach?

CRISPR is already proving it can cure rare diseases, as seen with recent breakthroughs in sickle cell anemia. By precisely editing genes, CRISPR can remove defective portions of the dystrophin gene, restoring function and offering real hope for those with DMD and BMD.